356 related articles for article (PubMed ID: 34002026)
1. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).
Chen CX; Hu F; Wei J; Yuan LT; Wen TM; Gale RP; Liang Y
Leukemia; 2021 Jun; 35(6):1661-1670. PubMed ID: 34002026
[TBL] [Abstract][Full Text] [Related]
2. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y
Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis.
Zhang J; Chen C; Yang Y; Yang J
Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063
[TBL] [Abstract][Full Text] [Related]
6. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
7. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.
Martínez-Sanz J; Muriel A; Ron R; Herrera S; Pérez-Molina JA; Moreno S; Serrano-Villar S
Clin Microbiol Infect; 2021 Feb; 27(2):238-243. PubMed ID: 32979572
[TBL] [Abstract][Full Text] [Related]
8. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
[TBL] [Abstract][Full Text] [Related]
10. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
Rezaei S; Fatemi B; Karimi Majd Z; Minaei H; Peikanpour M; Anjidani N; Taheri A; Dastan F; Mosaed R
Expert Rev Clin Immunol; 2021 May; 17(5):499-511. PubMed ID: 33823733
[TBL] [Abstract][Full Text] [Related]
12. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
Mahroum N; Watad A; Bridgewood C; Mansour M; Nasr A; Hussein A; Khamisy-Farah R; Farah R; Gendelman O; Lidar M; Shoenfeld Y; Amital H; Kong JD; Wu J; Bragazzi NL; McGonagle D
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501738
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
15. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.
Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R
Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.
Martínez-Guerra BA; de-León-Cividanes NA; Tamez-Torres KM; Román-Montes CM; Rajme-López S; Ortiz-Brizuela E; Aguilar-Salinas CA; Sierra-Madero J; Sifuentes-Osornio J; Ponce-de-León A; González-Lara MF
Rev Invest Clin; 2022 Jan; 74(1):40-50. PubMed ID: 34618802
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
Selvaraj V; Khan MS; Bavishi C; Dapaah-Afriyie K; Finn A; Lal A; Mylonakis E
Lung; 2021 Jun; 199(3):239-248. PubMed ID: 34050796
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]